Getinge continues to focus on advancing patient care in cardiovascular and cardiothoracic procedures
Getinge announces its commitment to the European Association for Cardio-Thoracic Surgery (EACTS) meeting, supporting the advanced education in the field of cardiac, thoracic and vascular interventions.
For more than 50 years, coronary artery bypass graft (CABG) surgery has been the standard of care for revascularization of patients with coronary artery disease¹. Today’s CABG patient has a higher risk profile due to multiple co-morbidities, which contributes to an increase in surgical complexity, perioperative complications and cost². These patients present new challenges and have specific resource requirements, from pre-operative stabilization to intra-operative treatment and post-operative recovery. Getinge’s innovations can help enhance patient care, reduce operational costs and contribute to a positive patient experience³.
As a partner for cardiothoracic procedures, Getinge offers medical technology and expertise to improve the clinical experience before, during and after surgery. “Getinge has more than 40 years experience in this field and working closely with our customers and associations such as EACTS, we have a shared goal of advancing patient care” shared Markus Stirner-Schilling, Senior Director, Acute Care Therapies, Global Commercial Operations.
To support our expertise in coronary artery bypass graft (CABG) surgery, Getinge provides the Endoscopic Vessel Harvesting (EVH) systems. There have been over 2.5 million EVH procedures worldwide and each new generation of this unique technology has been developed in partnership with the specialists who use them in daily practice. This procedure is at the forefront of technological advances that improve vessel harvesting for coronary artery bypass graft (CABG) surgery. The EVH procedure leads to faster recovery, better clinical outcomes, and enhanced patient satisfaction.
Learn more about CABG and Getinge’s solutions here
This international congress will see Getinge present products in the Cardio-Thoracic Surgery segment, including Cardiohelp, Cardiosave and Endoscopic Vessel Harvesting. On the booth will also be the next generation Heart-Lung Machine HL 40*. HL 40* is inspired by perfusionists with enhanced usability, safety and flexibility (*CE mark pending). Getinge will also support the training program during this event with the presentation of ‘No touch aortic off-pump coronary artery bypass’ case during the Techno-College session and also Heartstring devices will be used in the Coronary Training Suite.
About European Association for Cardio-Thoracic Surgery
The EACTS Annual Meeting is the largest cardio-thoracic meeting in the world focusing on scientific developments and research in the following specialities: Acquired Cardiac Disease, Congenital Heart Disease, Vascular Disease and Thoracic Disease.
About Getinge at EACTS
Registered delegates are invited to visit Getinge on booth 239, Hall 2, CCL – Centro de Congerssos de Lisboa, Praca das Industrias, 1 1300-307 Lisbon, Portugal from October 3-5, 2019.
*The HL 40 may be pending regulatory approvals to be marketed in your country. Please contact your Getinge representative for more information.
Media Contact
Tracey Dawe
Director Communications
Phone: + 44 77 177 84965
Email: tracey.dawe@getinge.com
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.
¹ European Heart Journal, Volume 34, Issue 37, 1 October 2013, Pages 2862–2872 https://academic.oup.com/eurheartj/article/34/37/2862/503604
² Cost of Individual complications following coronary artery bypass grafting. J Thorac Cardiovasc Sug 2018;155:875-82.
³ Data on file
Tags: